Rowan University
Institutional Biosafety Committee (IBC) Meeting Minutes

Meeting Date: July 10, 2025
Meeting Time: 11:05 AM – 12:49 PM
Meeting Location: Microsoft Teams
Chair: Dr. Kevin Currie

Voting Members:

Member	Role/Expertise	Present	Excused
Dr. K.C.	Chair	x	
Dr. L.P.	Scientist	x	
Dr. B.W.	Scientist	x	
Dr. C.K.	Scientist	x	
Dr. M.F.	Plant Expert	x	
Dr. E.M.	Animal Expert	x	
Mr. E.G.	Research Compliance Director	x	
Mr. T.B.	Biological Safety Officer	x	
Mr. S.G.	Non-affiliated		x
Mr. R.H.	Non-affiliated		x

Guests: Ms. S.S. (Notetaker)
Quorum: The committee has ten voting members, and eight members were present.

I. Call to Order and Conflicts of Interest
The IBC Chair called the meeting to order at 11:05 AM and reminded all members present to identify any conflicts of interest as each registration is reviewed.

II. Review and approval of agenda
The July 10, 2025, agenda was approved unanimously.

III. Review and approval of prior meeting minutes
Motion: Approve the June 5, 2025, meeting minutes as written.
Votes: 8 For, 0 Against, 0 Abstain

IV. Review of Prior Business – Nothing to report

V. Institutional Review Entity (IRE) - The Institutional Dual Use Research Contact (IDURC) did not receive any notifications about dual use concerns nor received any contact from researchers using select agents/toxins.

VI. Chairman's Report - Nothing to report

VII. Biological Safety Officer (BSO) / Environmental Health & Safety (EH&S) Report
A. No issues of concern were raised. Personnel training and lab inspection report was summarized by BSO.

VIII. New Business
A. Pandey Lab Biological Registration - Renewal
a. **PI**: Manoj Pandey
b. **Project Title and #:**
i. Development of Novel BTK Inhibitor, #67
c. NIH Sponsored: Yes
d. Summary: The project aims to treat multiple myeloma (MM) by blocking two important parts of the cancer cells at the same time: a protein called BTK, which helps the cells grow and survive and microtubules which are structures inside cells that help them divide and move. Both of these targets are essential for cancer cells to function, but no one has yet tried to block them together in MM.
e. **Risk Assessment:** Biosafety Level 2
f. **Personnel Training:** Required laboratory personnel training completed: General Laboratory, Biological Laboratory, r/sDNA, and Hazardous Biological.
g. **NIH Guidelines Sections for Research with Recombinant or Synthetic Nucleic Acid Molecules:** Section III-D-4,4-a, 4-c(s); Section III F-1,2,3
h. **Committee Deliberation and Motion**: Requires modifications with full committee review of clarifications and additional details:
i. Clarification on use of respirator
ii. Additional information for associated biological materials
iii. Revisions to viral vector registration form CW307908
iv. Revisions to Recombinant or Synthetic Nucleic Acid Molecules Survey
v. Update ABSL on Risk Assessment and Associated Biological Materials
vi. Include viral vector registration form for lentivirus

Vote: 8 in favor, 0 opposed, 0 abstained

B. Niedinghaus-West Lab Biological Registration - Renewal
a. **PI**: Elizabeth Niedinghaus-West
b. **Project Title and #:** Neural circuitry mediating behavioral flexibility, #71
c. **NIH Sponsored: Yes**
d. Summary: The project studies the ability to shift behavior in the face of negative consequences for survival (i.e., cognitive or behavioral flexibility). People with substance abuse disorders (SUDs) often have difficulty altering their behavior to respond to maladaptive consequences, leading to poor decision-making. In the rat, a history of cocaine impairs the ability to adjust behavior away from reward-predictive cues following reward devaluation, a canonical measure of behavioral flexibility. (i.e., cocaine leads to inflexible behavior). The specific aims are to determine the brain circuitry required for behavioral flexibility using state-of-the art optogenetic techniques, which allow high spatial and temporal resolution for

manipulating brain activity. The goal is to identify the role for different brain circuits (PFC to midbrain, PFC to striatum, PFC to amygdala) in complex behavioral flexibility tasks.

e. **Risk Assessment:** Biosafety Level 1; Animal Biosafety Level 1
f. **Personnel Training:** Required laboratory personnel training completed: General Laboratory, Biological Laboratory, r/sDNA, and Hazardous Biological.
g. **NIH Guidelines Sections for Research with Recombinant or Synthetic Nucleic Acid Molecules:** Section III D-4, 4-a, 4-c-(2); Section III-E-3
h. **Committee Deliberation and Motion**: Approval of biological registration with administrative review pending minor clarifications/additional details:
    i. Clarification on Recombinant or Synthetic Nucleic Acid Molecules Survey
    ii. Edits to biological source materials
    iii. Additional information/clarification on viral vector forms

    Vote: 8 in favor, 0 opposed, 0 abstained

M.F. recused at 12:00 PM

IX. For the Good of the Committee 12:28 PM

X. Meeting Adjournment: The IBC Chair moved to adjourn the meeting 12:91 PM.